🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Prospective Study to Determine the Prevalence of Signs of Central Sensitization in Adults With ASD Without Intellectual Developmental Disorders

Recruitingn/aAges 18 Years - anyAllGroupe Hospitalier Mutualiste de Grenoble
NCT07495761 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Autism is a neurodevelopmental disorder (NDD) characterized by two key features: persistent deficits in communication and social interaction, and restricted, repetitive patterns of behavior, interests, and activities. Ninety-five percent of children aged 3 to 6 with autism spectrum disorder (ASD) have sensory peculiarities. In adulthood, this figure remains at 90%. This atypical sensory processing has been part of the DSM diagnostic criteria since 2013. Each sense can be affected by hypo- or hypersensitivity. In the continuum of this particular sensory processing, pain, which is defined as an unpleasant sensory and emotional experience, can be very present but also difficult to detect and manage. It is now established that there are other characteristics that impact pain in ASD: information processing time may be longer, referred to as "latency time," but there are also difficulties in

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age ≥ 18 years 2. Medical diagnosis of ASD without established intellectual developmental disorder 3. Patient affiliated with a social security system or beneficiary of such a system 4. Understanding of written French (good comprehension of self-questionnaire questions) 5. No objection from the patient to participate in the study Exclusion Criteria: 1. Intellectual developmental disorder that prevents understanding of self-administered questionnaires 2. Individuals subject to legal or judicial protection measures or unable to express their consent
💊

What it tests

  • Not listed
📍

Where

1 site
Groupe Hospitalier Mutualiste de Grenoble
Grenoble, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy